E G MacEwen
Overview
Explore the profile of E G MacEwen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1448
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marr A, Thamm D, Kurzman I, Vail D, MacEwen E
Vet Comp Oncol
. 2009 Apr;
1(3):159-67.
PMID: 19379315
The in vitro antiproliferative, apoptotic and cell-cycle effects of 2-methoxyestradiol (2ME(2)), an endogenous oestrogen metabolite, were investigated using a variety of canine tumour cell lines. The cells were cultured under...
2.
Alexander A, Huelsmeyer M, Mitzey A, Dubielzig R, Kurzman I, MacEwen E, et al.
Cancer Immunol Immunother
. 2005 Jun;
55(4):433-42.
PMID: 15965647
A xenogeneic melanoma-antigen-enhanced allogeneic tumor cell vaccine (ATCV) is an appealing strategy for anti-cancer immunotherapy due to its relative ease of production, and the theoretical possibility that presentation of a...
3.
Kemnitz J, Roecker E, Haffa A, Pinheiro J, Kurzman I, Ramsey J, et al.
J Med Primatol
. 2001 Feb;
29(5):330-7.
PMID: 11168823
Cross-sectional studies of humans have shown that dehydroepiandrosterone sulfate (DHEAS) peaks shortly after sexual maturation and declines thereafter, suggesting that the progressive reduction in DHEAS may play a role in...
4.
Vail D, MacEwen E
Cancer Invest
. 2000 Dec;
18(8):781-92.
PMID: 11107448
Spontaneous tumors in companion animals (dog and cat) offer a unique opportunity as models for human cancer biology and translational cancer therapeutics. The relatively high incidence of some cancers, similar...
5.
Chun R, Kurzman I, Couto C, Klausner J, Henry C, MacEwen E
J Vet Intern Med
. 2000 Sep;
14(5):495-8.
PMID: 11012111
Sixteen dogs with histologically confirmed appendicular osteosarcoma were treated by amputation followed by cisplatin and doxorubicin chemotherapy. All dogs began chemotherapy within 24 hours of surgery. Cisplatin was administered at...
6.
Fox L, Rosenthal R, King R, Levine P, Vail D, Helfand S, et al.
Am J Vet Res
. 2000 Jul;
61(7):791-5.
PMID: 10895902
Objective: To determine clinical response and toxic effects of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP) administered i.v. at escalating doses to cats with oral squamous cell carcinoma (SCC). Animals: 18 cats with...
7.
Kurzman I, Shi F, Vail D, MacEwen E
Cancer Biother Radiopharm
. 2000 Jun;
14(2):121-8.
PMID: 10850295
The combination of chemotherapy with immunotherapy may offer an advantage over either therapy alone and provide a greater potential for total tumor eradication. Monocyte/macrophage-mediated tumor cell killing is a major...
8.
MacEwen E, Kurzman I, Vail D, Dubielzig R, Everlith K, Madewell B, et al.
Clin Cancer Res
. 2000 Jan;
5(12):4249-58.
PMID: 10632367
Spontaneous canine oral melanoma (COM) is a highly metastatic cancer, resistant to chemotherapy, and can serve as a model for cancer immunotherapy. Liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) can activate the tumoricidal...
9.
Soergel S, MacEwen E, Vail D, Potter D, Sondel P, Helfand S
J Immunother
. 1999 Nov;
22(5):443-53.
PMID: 10546161
A variety of immune cell activators can enhance the cytotoxic effects of monocytes/macrophages including interferon-gamma (IFN-gamma) and muramyl peptides, which are under investigation for cancer therapy in humans and dogs....
10.
Hogge G, Burkholder J, Culp J, Albertini M, Dubielzig R, Yang N, et al.
Cancer Gene Ther
. 1999 Mar;
6(1):26-36.
PMID: 10078961
Tumor vaccines and gene therapy have received significant attention as means of increasing cellular and humoral immune responses to cancer. We conducted a pilot study of seven research dogs to...